argenx names Karen Massey as new CEO
argenx announced leadership changes and shareholder voting results from its Annual General Meeting.
Rhea-AI Filing Summary
argenx announced leadership changes and shareholder voting results from its Annual General Meeting. The Board of Directors appointed Karen Massey as Chief Executive Officer, succeeding co-founder Tim Van Hauwermeiren, who becomes Chairperson of the Board as a non-executive director.
Massey joined argenx in March 2023 as Chief Operating Officer and has been central to execution and long-term growth strategy, according to the Board. At the General Meeting, 90.9% of the company’s share capital was represented and all agenda items received the required majority of votes in favor.
Positive
- None.
Negative
- None.
Insights
argenx executes planned CEO handover while maintaining founder influence as Board chair.
argenx is transitioning leadership by elevating Karen Massey from Chief Operating Officer to Chief Executive Officer, while co-founder Tim Van Hauwermeiren moves to Chairperson of the Board as a non-executive director. This preserves continuity at the board level while shifting day-to-day leadership.
Massey has been involved in argenx’s execution and long-term growth strategy since joining as COO in March 2023, suggesting familiarity with current operations and pipeline direction. The Board highlights her leadership focus on patients, company culture, and pipeline development, aligning her role with the existing strategic trajectory.
Shareholder support appears strong, with 90.9% of share capital represented at the Annual General Meeting and all agenda items receiving the required majority of votes. This broad backing indicates alignment between shareholders, the Board, and the new leadership structure at this stage.
Key Figures
Key Terms
Annual General Meeting financial
Chief Executive Officer financial
non-executive director financial
neonatal Fc receptor (FcRn) blocker medical
Immunology Innovation Program (IIP) technical
FAQ
What leadership changes did argenx (ARGX) announce in this Form 6-K?
Who is Karen Massey, the new CEO of argenx (ARGX)?
What role will co-founder Tim Van Hauwermeiren hold at argenx (ARGX) now?
Were argenx’s (ARGX) Annual General Meeting proposals approved?
Where can investors find detailed voting results for argenx’s (ARGX) Annual General Meeting?
What does argenx (ARGX) focus on as a company?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2026
Commission File Number: 001-38097
ARGENX SE
(Translation of registrant’s name into English)
Laarderhoogtweg 25
1101 EB Amsterdam, the Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
On May 6, 2026, argenx SE (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information contained in this Current Report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the Company’s Registration Statements on Forms S-8 (File Nos. 333-225375, 333-258253, 333-274721, and 333-292200), and to be part thereof from the date on which this Current Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
| Exhibit | Description | |
| 99.1 | Press Release May 6, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ARGENX SE | ||
| Date: May 6, 2026 | By: | /s/ Hemamalini (Malini) Moorthy |
| Name: Hemamalini (Malini) Moorthy | ||
| Title: General Counsel | ||
Exhibit 99.1
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
Leadership transition marks next evolution of growth
May 6, 2026
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General Meeting of shareholders and the Board of Directors’ appointment of Karen Massey as Chief Executive Officer and Tim Van Hauwermeiren as Chairperson of the Board of Directors.
“Karen has earned the full confidence of the Board of Directors and our shareholders,” said Tim Van Hauwermeiren, Chair of the Board of Directors. “She is a proven leader who has played a central role in shaping argenx’s execution and long-term growth strategy. Karen leads with our responsibility to patients, the argenx culture, and a vision to continue to build our pipeline. I look forward to supporting Karen and the leadership team as argenx enters its next phase of growth.”
Karen Massey joined argenx in March 2023 as Chief Operating Officer and will succeed Tim Van Hauwermeiren, who co-founded argenx and has served as Chief Executive Officer since 2008. Her appointment by the Board of Directors as CEO follows shareholder approval of her appointment as executive director of the Board of Directors. The Board of Directors also appointed Tim Van Hauwermeiren as Chairperson of the Board of Directors, effective immediately, following his appointment as non-executive director to the Board of Directors at the General Meeting.
90.9% of the Company’s share capital was represented at the General Meeting.
All items on the agenda received the required majority of votes in favor for approval, including:
| · | argenx 2025 remuneration report |
| · | argenx annual report and annual accounts for the financial year ending December 31, 2025 |
| · | Allocation of the Company’s 2025 profits to the retained earnings |
| · | Karen Massey has been appointed as an executive director to the Board of Directors for a term of 4 years |
| · | Tim Van Hauwermeiren has been appointed as a non-executive director to the Board of Directors for a term of 4 years |
| · | Ana Céspedes has been reappointed as non-executive director to the Board of Directors for a term of 4 years |
| · | Camilla Sylvest has been reappointed as non-executive director to the Board of Directors for a term of 4 years |
| · | Pam Klein has been reappointed as non-executive director to the Board of Directors for a term of 2 years |
| · | Authorization to issue shares and grant rights to subscribe for shares in the share capital of the Company for up to 10% of the outstanding share capital at the date of the meeting and for a period of 18 months from the meeting and to limit or exclude statutory pre-emptive rights |
The voting result and all documents relating to the shareholders’ meeting will be available on the argenx
website at www.argenx.com/investors/shareholder-meetings.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com